INTRODUCTION
Increased translocation of intestinal bacteria is common in patients with chronic liver disease and causes characteristic infectious complications in advanced disease stages (Cirera et al., 2001; Schuppan and Afdhal, 2008; Tandon and GarciaTsao, 2008) . In addition, translocation of bacterial components termed pathogen-associated molecular patterns (PAMPs) triggers inflammatory responses through Toll-like receptors (TLRs) in both early and late disease stages (Dolganiuc et al., 2007; Fukui et al., 1991; Nolan and Leibowitz, 1978; Seki et al., 2007; Wiest and Garcia-Tsao, 2005) . Moreover, PAMPs from the intestinal microbiota and TLR4 contribute to liver fibrosis and cirrhosis (Broitman et al., 1964; Rutenburg et al., 1957; Seki et al., 2007) . Notably, 80% of hepatocellular carcinomas (HCCs) develop in fibrotic or cirrhotic livers as a consequence of chronic liver injury (Fattovich et al., 2004; Luedde and Schwabe, 2011) , with HCC being the leading cause of death in patients with compensated liver cirrhosis (Fattovich et al., 2004) . However, pathways that are responsible for the high rate of HCC development in the chronically injured and fibrotic liver remain largely unknown. Here, we hypothesize that inflammatory and fibrogenic
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Hepatocellular carcinoma (HCC) typically develops in chronically injured livers, but mediators that promote HCC in this setting are not well characterized. Our study demonstrates that TLR4 activation by lipopolysaccharide from the intestinal microbiota contributes to injury-and inflammation-driven tumor promotion but not to tumor initiation. Different from most previous studies that focused on inflammatory pathways in bone marrow-derived cells, our study finds that the LPS-TLR4 pathway promotes HCC by increasing proliferative and antiapoptotic signals in non-bone marrow-derived resident liver cells. Our finding that gut sterilization efficiently prevents HCC even at very late stages may provide a basis for clinically applicable HCC prevention strategies in patients with chronic liver injury.
responses induced by the gut microbiota and TLRs contribute to hepatocarcinogenesis and might represent targets for HCC prevention or treatment.
RESULTS

TLR4 Is Required for Hepatocarcinogenesis in the Chronically-Injured Liver
To determine whether the known contribution of TLRs to hepatic inflammation and fibrosis may set the stage for HCC development, we subjected C3H/HeJ and C3H/HeOuJ mice, which carry a nonfunctional and the wild-type Tlr4, respectively, to a combination of diethylnitrosamine (DEN) and the hepatotoxin carbon tetrachloride (CCl 4 ). This model incorporates chronic injury, inflammation, fibrogenesis, and CCl 4 -mediated increases of endotoxin levels (Seki et al., 2007) and thus shares several features with the microenvironment in which the majority of human HCCs arise. Tumors developing by this regimen showed WT mice (n = 10) and Tlr4 mut (n = 9) were injected with DEN (100 mg/kg i.p.) at the age of 12 weeks followed by six injections of CCl 4 (0.5 ml/kg i.p.) and sacrificed 10.5 months after DEN. Shown are tumor number, largest tumor size, liver:body weight ratio, H&E sections, and representative images.
(B) Tlr4 WT (n = 14) and Tlr4 mut mice (n = 15) were treated with DEN followed by two injections of CCl 4 . Gene expression and ALT and AST levels were determined 48 hr after the second CCl 4 injection. Fold induction in comparison to untreated livers. Data are represented as means ± SD. *p < 0.05. **p < 0.01. See also Figure S1 . Figure 1A ). Taking advantage of the separate initiation and promotion stages in this model, we further analyzed the contribution of TLR4 at these stages. Following DEN injection, we observed no differences in the induction of inflammatory genes Il6 and Ccl2 and p53-dependent genes Cdkn1a and Bax between Tlr4 WT and Tlr4 mut mice ( Figure S1A available online). DEN-induced liver injury, as determined by serum ALT and AST levels, was exacerbated in Tlr4 mut mice ( Figure S1A ). However, the increased liver injury is unlikely to cause decreased hepatocarcinogenesis in Tlr4 mut mice, as liver injury after DEN is thought to promote hepatocarcinogenesis by inducing regenerative responses (Maeda et al., 2005; Naugler et al., 2007) . Moreover, despite a small trend toward decreased HCC development, all Tlr4 mut mice subjected to a purely genotoxic hepatocarcinogenesis protocol developed numerous large tumors ( Figure S1B ). Thus, TLR4 status exerts no major effect on genotoxic tumor initiation apart from an increased susceptibility of Tlr4 mut mice to liver injury. In contrast, we observed a significant impact of TLR4 status on tumor promotion by CCl 4 , with proliferation markers mKi67, Pcna, Ccnb1, and Ccnb2; hepatic fibrogenesis markers Col1a1 and Acta2; and inflammatory markers Il6, Il1b, Tnf, and Ccl2 strongly reduced in Tlr4 mut mice, as evidenced by microarray (data not shown) and qPCR analysis, despite increased liver injury ( Figure 1B ; Figures S1C and S1D). Similar differences were observed after DEN plus four CCl 4 injections, suggesting a lasting effect of absent TLR4 signaling ( Figure S1D ). While CCl 4 plus DEN-induced liver injury was increased in Tlr4 mut mice 48 hr after the last CCl 4 injection, it was similar to Tlr4 WT at earlier time points ( Figure S1E ), suggesting that the Tlr4 mut mice have a defect in DEN plus CCl 4 -induced injury resolution and wound healing rather than a higher susceptibility to the initial injury. As chronic regeneration contributes to replicationinduced mutagenesis and HCC, we confirmed the reduction of proliferation using Tlr4 knockout (Tlr4 KO ) mice in C57Bl/6 background and Ki-67 immunohistochemistry (Figures S1F and S1G) .
To exclude that our findings reflect a particular role for TLR4 in the response to CCl 4 , we tested two additional models in which DEN was combined with thioacetamide or a choline-deficient diet and found essentially the same results with decreased prolif- The right heatmap shows genes fulfilling the same conditions as described earlier restricted to the GO categories 0007049, 0009611, and 0005578. Data are represented as means ± SD. *p < 0.05. **p < 0.01. See also Figure S2 .
eration and fibrogenesis (Figures S1H-S1J). We also tested whether TLR2, which recognizes PAMPs from the grampositive bacterial microbiota, contributes to hepatocarcinogenesis. However, we did not find a role for TLR2 in DEN plus CCl 4 -induced proliferation or HCC development ( Figures S1K and S1L ).
The Intestinal Microbiota and Lipopolysaccharide Promote Hepatocarcinogenesis Next, we examined whether ligands from the bacterial intestinal microbiota are triggers for the observed TLR4-dependent tumor promotion. For this purpose, we gut-sterilized mice with a well-established cocktail of oral antibiotics that eliminates commensal bacteria (Rakoff-Nahoum et al., 2004) and reduces systemic lipopolysaccaride (LPS) levels (Seki et al., 2007) . This treatment resulted in not only a >99.5% reduction of 16s levels in the cecum ( Figure S2A ) and an enlargement of the cecum commonly observed in germfree (GF) mice (Figure 2A ) but also a highly significant reduction of tumor number, size, and the liver:body weight ratio in our DEN plus CCl 4 HCC model
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The Intestinal Microbiota, TLR4, and HCC ( Figure 2A ). Similar to data in the Tlr4 mut mice, tumor incidence was not affected by gut sterilization (100% in gut-sterilized vs. 100% in control mice). In addition to the similar degree of HCC reduction, gut sterilization markedly phenocopied events observed in the Tlr4 mut mice such as reduced expression of cell cycle, fibrosis, and inflammatory genes and increased liver injury ( Figure 2B ; Figure S2B ). Accordingly, the great majority of 1,752 genes that were significantly up-or downregulated by DEN plus CCl 4 and significantly up-or downregulated by TLR4 inactivation were concordantly regulated in DEN plus CCl 4 -treated liver from gut-sterilized mice (r = 0.794, p < 0.0001), suggesting that TLR4 inactivation and gut sterilization exert highly similar biological effects on the liver during hepatocarcinogenesis ( Figure 2C ). Like Tlr4 mut mice, gut-sterilized mice also did not show differences in inflammatory and p53-dependent gene expression in response to acute DEN treatment but displayed increased liver injury ( Figure S2C ). As a third approach in addition to TLR4 inactivation and gut sterilization, we treated mice with a low, nontoxic dose of LPS via subcutaneous osmotic pumps for 12 weeks during DEN plus CCl 4 -induced hepatocarcinogenesis. This low-dose LPS treatment led to a significant increase in inflammatory gene expression, tumor number, tumor size and liver:body weight ratio ( Figure 3A ; Figure S3 ), further confirming our hypothesis that the LPS-TLR4 pathway promotes hepatocarcinogenesis. As Tlr5-deficient mice have an altered gut microbiome (Vijay-Kumar et al., 2010) , it is conceivable that TLR4 might also affect the composition of the gut microbiome and thereby influence HCC development rather than exerting direct effects in the liver. To address this possibility, we first performed 16s-based pyrosequencing of the cecal gut microbiota of wild-type and Tlr4 mut mice as well as mice treated with PBS or LPS. Unifrac analysis revealed no significant differences between Tlr4
WT and Tlr4 mut mice, or between PBS-and LPS-treated mice, but showed distinct clustering of the gutsterilized mice ( Figure 3B ). It is interesting that differences between these two independent experiments were larger in the Unifrac analysis than differences between Tlr4 WT and Tlr4 mut mice, or PBS-and LPS-treated mice, again underlining that LPS and TLR4 status exert no significant influence on the composition of the gut microbiome. Moreover, the taxonomic distribution of the cecal gut microbiome was similar between Tlr4 WT and Tlr4 mut mice, and PBS-and LPS-treated mice (Figure 3C) ; among the 118 detected taxa at the genus level, we found no significant differences between Tlr4 WT and Tlr4 mut mice and only one taxon (firmicutes;bacilli;other;other;other) with a significant but modest difference between PBS-treated mice (8.1% abundance) and LPS-treated mice (4.7% abundance). However, as there was no difference in this taxon between Tlr4 WT and Tlr4 mut mice, it is extremely unlikely that
The Intestinal Microbiota, TLR4, and HCC the different abundance of this taxon is responsible for differences in hepatocarcinogenesis.
As a fourth approach, we investigated DEN plus CCl 4 -induced hepatocarcinogenesis in GF and littermate controls that had been transferred to a specific-pathogen-free (SPF) environment after the initial DEN injection. GF mice displayed the typical enlargement of the cecum and had a significantly reduced tumor number, tumor size, and liver:body weight ratio in comparison to SPF mice (Figures 4A and 4B) , thus confirming results in mice gut-sterilized by antibiotics and excluding that effects of antibiotics on the liver were responsible for HCC reduction.
Non-Bone-Marrow-Derived Resident Hepatic Cells Mediate the Tumor-Promoting Effect of TLR4
To determine the hepatic cell that promotes HCC in response to TLR4 activation, we generated TLR4-chimeric mice using a combination of irradiation, bone marrow transplantation (BMT), and liposomal clodronate-mediated macrophage depletion (Seki et al., 2009; Seki et al., 2007) . This protocol achieved >97% suppression of LPS responses after transplantation of Tlr4 mut bone marrow into Tlr4 WT mice, almost complete restoration of LPS responses after transplantation of Tlr4 WT bone marrow into Tlr4 mut mice, and substitution of F4/80-positive hepatic macrophages ( Figure S4A ). DEN plus CCl 4 -induced hepatocarcinogenesis in TLR4-chimeric mice revealed no significant reduction of HCC number, size, and liver:body weight ratio in mice transplanted with Tlr4 mut bone marrow, whereas TLR4 inactivation in resident (defined hereby as non-bone-marrowderived) liver cells significantly reduced HCC number, size, and liver:body weight ratio ( Figure 5A ). Similarly, the induction of mKi67 and Pcna mRNA in response to acute DEN plus Figure 5B) . Moreover, the depletion of hepatic macrophages by liposomal clodronate did not affect the response to DEN plus CCl 4 , as evident by mKi67 and Pcna mRNA levels ( Figure S4B ). To determine the resident liver cell that was responsive to LPS, we injected a sublethal dose of LPS into healthy mice and mice that had undergone DEN plus eight CCl 4 treatments, followed by determination of NF-kB p65 translocation. To avoid the known rapid release of tumor necrosis factor (TNF) and subsequent TNF-mediated NF-kB activation as a cofounding factor, we used either (a) TLR4-chimeric mice with Tlr4 mut bone marrow, (b) macrophage-depleted mice, or (c) mice deficient for both TNFR1 and IL-1R1 for this experiment.
In uninjured liver, we observed strong NF-kB p65 nuclear translocation in desmin-positive hepatic stellate cells and Kupffer cells but no translocation in hepatocytes after LPS injection (Figure S4C ). In mice that had undergone DEN plus CCl 4 treatment, we confirmed p65 nuclear translocation in hepatic stellate cells but also observed p65 translocation in a large percentage of hepatocytes ( Figure 5C ; Figure S4D ), suggesting that both hepatocytes and hepatic stellate are candidates for TLR4-dependent tumor promotion in the chronically injured liver.
Epiregulin Is a TLR4-Regulated Hepatomitogen that Promotes Hepatocarcinogenesis
Microarray analysis demonstrated cell cycle-related genes as most significantly affected by TLR4 status or gut sterilization ( Figure 2C ). Our microarray and subsequent qPCR analysis revealed reduced expression of two hepatomitogens, HGF and epiregulin (Toyoda et al., 1995) , in livers from DEN plus CCl 4 -treated Tlr4 mut and gut-sterilized mice as well as from TLR4-chimeric mice with Tlr4 mut in resident liver and Tlr4 WT bone marrow ( Figures 6A and 6C ). Both HGF mRNA (data not shown) and epiregulin mRNA were expressed much higher in hepatic stellate cells than in whole liver, hepatocytes, or hepatic macrophages ( Figure 6D ). As the role of HGF in hepatocarcinogenesis remains controversial (Sakata et al., 1996; Santoni-Rugiu et al., 1996; Takami et al., 2007) , we focused our attention on epiregulin. Hepatic stellate cells isolated from fibrotic livers secreted significantly more epiregulin than quiescent hepatic stellate cells ( Figure 6D ), and stimulation of hepatic stellate cells with LPS significantly upregulated epiregulin mRNA and protein in an NF-kB dependent manner ( Figure 6E ). Moreover, LPS injection into mice either as a bolus or via the aforementioned chronic subcutaneous infusion also significantly increased epiregulin expression in the liver ( Figure 6D ; Figure S3 ). Epiregulin mRNA expression was also induced by LPS in human hepatic stellate cells and upregulated in livers of patients with alcoholic hepatitis, a group of patients with typically very high LPS levels (Fukui et al., 1991) ( Figure 6F ). To elucidate the contribution of epiregulin to hepatocarcinogenesis, we subjected wild-type and epiregulin-deficient (Ereg KO ) mice to DEN plus CCl 4 -mediated hepatocarcinogenesis. Due to the much lower propensity of C57Bl/6 mice to develop HCC, we used an altered protocol in which mice were subjected to DEN at Day 15 postpartum, followed by multiple CCl 4 injections. Ereg KO mice displayed a significant reduction of tumor number, size, and the liver:body weight ratio, albeit to a much lesser degree than Tlr4 mut mice ( Figure 6G ). Moreover, (B) Tumor number, size, and liver:body weight ratio was determined in SPF mice (n = 9) and GF mice (n = 10). Data are represented as means ± SD. *p < 0.05. **p < 0.01.
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The Intestinal Microbiota, TLR4, and HCC epiregulin was not upregulated at late stages in our hepatocarcinogenesis model and did not differ between wild-type, Tlr4 mut , and gut-sterilized mice at these stages of hepatocarcinogenesis ( Figure 6H ). Thus, additional factors must be responsible for the striking reduction of hepatocarcinogenesis in Tlr4 mut and gutsterilized mice.
The Intestinal Microbiota and TLR4 Suppress Apoptosis in Late Stage of Hepatocarcinogenesis Next, we attempted to establish the time frame during which bacterial PAMPs exert the most profound effects on hepatocarcinogenesis. Surprisingly, gut sterilization during the first 4.5 months of hepatocarcinogenesis showed only a moderate decrease of hepatocarcinogenesis ( Figure 7A ). In contrast, gut sterilization during the last 4 months of hepatocarcinogenesis reduced tumor number and size by 90% and 70%, respectively, and almost normalized the liver:body weight ratio ( Figure 7A ). At Figure 7B ), suggesting that gut sterilization prevented tumor development rather than leading to the regression of already established tumors. We additionally tested whether more selective gut decontamination with rifaximin, a widely used nonabsorbable antibiotic for the prevention of hepatic encephalopathy in patients with endstage liver disease (Bass et al., 2010) , could influence hepatocarcinogenesis at late stages. We observed a borderline significant reduction of tumor numbers but saw no significant reduction in tumor size (data not shown), suggesting only moderate efficacy of rifaximin monotherapy on hepatocarcinogenesis at late stages ( Figure S5 ).
To determine whether gut sterilization might affect already established tumors, we treated wild-type mice at a time point where tumors were already present with the quadruple antibiotics cocktail for 6 weeks. However, we found no significant change of tumor size, number, or liver:body weight ratio in comparison to control mice ( Figure 7C ). When following single tumors by weekly ultrasound monitoring, we also saw no change in tumor size in antibiotics-treated mice (data not shown).
To further determine the mechanism by which the intestinal microbiota and TLR4 promote hepatocarcinogenesis, we analyzed gene expression, proliferation, and apoptosis in gutsterilized and Tlr4 mut mice. Due to the lower tumor number
The Intestinal Microbiota, TLR4, and HCC and size, the overall amount of Ki-67 staining in Tlr4 mut and gutsterilized mice was expectedly lower (data not shown). Microarray comparison showed a highly similar gene expression pattern in HCC from wild-type, Tlr4 mut , and gut-sterilized mice (Figure S6A) , and HCCs from these groups did not cluster separately as shown by dendrogram and Unifrac analysis ( Figures S6B-S6C ). There was a small but nonsignificant trend toward lower AFP and Ki-67 in HCCs from gut-sterilized mice and Tlr4 mut mice, which was most likely due to the smaller size of the tumors in these groups. There were no genes that showed significant changes, as defined by a corrected p value of < 0.05, in the Tlr4 mut or gut-sterilized HCC group when compared to the Tlr4 WT HCC group (data not shown). Moreover, there were no differences in tumor grade ( Figure S6D ), and there was a similar loss of collagen IV staining in HCCs from all groups ( Figure S6E ).
Microarray analysis showed no differences in expression of the cancer stem cell marker prominin 1/CD133 (data not shown), and we found only small and very rare clusters of cells positive for the progenitor marker A6 (Engelhardt et al., 1990) , with mostly low A6 expression and morphology of intermediate hepatobiliary cells (Figure S6F ). Similarly, there were only few cells with strong pan-cytokeratin signal typical for oval cells in tumors of all treatment groups and a larger but highly variable amount of cells with weak pan-cytokeratin expression typical of intermediate hepatobiliary cells in all groups (Figures S6G-S6H) . Altogether, the microarray and immunohistochemical data suggest that TLR4 signaling is unlikely to promote hepatocarcinogenesis via progenitor cells. There was also no significant difference in Ki-67 positive cells in nontumor liver between these groups, suggesting that TLR4 and the intestinal microbiota do not 
The Intestinal Microbiota, TLR4, and HCC promote tumor formation by increasing proliferation in nontumor liver ( Figure 8A ). Both gut-sterilized and Tlr4 mut mice displayed a significant increase in cleaved-caspase 3-positive cells with predominant expression of cleaved-caspase 3 in hepatocytes in nontumor areas ( Figure 8B) . Notably, the number of cleaved caspase 3-positive cells was inversely and highly significantly correlated with tumor number, size, and the liver:body weight ratio (Figure 8B) , further underlining the biological relevance of these findings. Significant increases in cleaved-caspase 3 positive cells and a strong and highly significant inverse correlation between cleaved-caspase 3 and tumor number, size, and liver:body weight ratio were also observed in mice that were gut-sterilized at late time points (Figures 8C and 8D) . Moreover, the expression of NF-kB-regulated antiapoptotic genes Birc3, Birc5, and Nos2 (Hatano et al., 2001; Wang et al., 1998) was reduced in nontumor areas of livers from Tlr4 mut and antibiotics-treated mice ( Figure 8E ), suggesting that TLR4 and the intestinal microbiota provide survival signals that are advantageous for hepatocarcinogenesis.
DISCUSSION
Chronic inflammation is a key contributor to carcinogenesis in various organs including the stomach, colon, lung, and liver (Balk- (A) Wild-type mice (C3H/HeOuJ) were treated with DEN (100 mg/kg i.p. at the age of 6 weeks) and 12 CCl 4 (0.5 ml/kg i.p.) injections and were either not gut sterilized (N, n = 7), gut sterilized starting 2 weeks before DEN injection until 2 weeks after the last CCl 4 injection (E, n = 10), or 2 weeks after the last CCl 4 injection until they were sacrificed (L, n = 8), followed by determination of tumor number, size, and liver:body weight ratio. (B) Wild-type mice treated as described earlier were sacrificed at the time point when the gutsterilization treatment was started to determine whether macroscopic or microscopic tumors were present. (C) Wild-type mice were treated with DEN (25 mg/kg i.p.) at Day 15 postpartum followed by 14 weekly injections of CCl 4 . After confirming the presence of tumor by ultrasound (data not shown), mice were treated with (Abx, n = 7) or without (Ctrl, n = 6) antibiotics (ampicillin, vancomycin, neomycin, and metronidazole) starting 2 weeks after the last CCl 4 injection. After 6 weeks of antibiotics, mice were sacrificed, and tumor number, size, and liver:body weight ratio was determined. Data are represented as means ± SD. *p < 0.05. **p < 0.01. ns, nonsignificant. See also Figure S5 . will and Mantovani, 2001; Grivennikov et al., 2010) . In the liver, 80% of HCCs develop in a microenvironment characterized by chronic injury, inflammation, and fibrosis. However, mediators that are responsible for the high risk to develop HCC in the chronically injured liver are largely unknown. Translocation of bacteria and bacterial PAMPs is common in chronic liver disease (Schuppan and Afdhal, 2008; Tandon and Garcia-Tsao, 2008) and promotes inflammation and fibrosis in chronic liver injury (Seki et al., 2007) .
We now provide several lines of evidence that the intestinal microbiota and TLR4 link inflammation and carcinogenesis in the chronically injured liver. Genetic TLR4 inactivation, gut sterilization, or GF status decrease HCC development by z80%. Conversely, prolonged treatment with low-dose LPS significantly increases HCC development. These findings are similar to intestinal tumorigenesis in which TLR4 and MyD88 drive carcinogenesis (Fukata et al., 2007; Lee et al., 2010; Rakoff-Nahoum and Medzhitov, 2007) . In contrast to the intestine, the liver is not in direct contact with intestinal bacteria. However, the liver is the first target of intestinal bacteria and PAMPs translocating into the portal circulation. Moreover, translocation increases with the development of liver fibrosis and cirrhosis (Fukui et al., 1991; Lin et al., 1995; Wiest and Garcia-Tsao, 2005) . Our HCC data in GF mice effectively exclude the possibility that the employed antibiotics with low systemic bioavailability might have exerted direct effects on the liver in our model. Moreover, 16s pyrosequencing demonstrated that TLR4 status and LPS treatment do not significantly change
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The Intestinal Microbiota, TLR4, and HCC the composition of the gut microbiome, with the exception of one taxon whose abundance differed between LPS-and PBStreated mice but not between Tlr4 WT and Tlr4 mut mice.
In contrast to a previous study , we find no significant contribution of the intestinal microbiota and TLR4 to tumor initiation or purely genotoxic hepatocarcinogenesis but demonstrate two distinct mechanisms through which the intestinal microbiota and TLR4 promote HCC: In early stages, TLR4 deficiency and gut sterilization decrease hepatic proliferation and fibrogenesis. Accordingly, gut sterilization or LPS infusion given during early stages moderately decrease or increase hepatocarcinogenesis, respectively. Our study provides evidence that TLR4-dependent HCC promotion in the early phases is predominantly mediated by TLR4-dependent secretion of growth factors such as epiregulin by hepatic stellate cells. Thus, hepatic stellate cells might provide a link between fibrosis and HCC development by increasing growth factors. Based on WT were either not gut sterilized (n = 7) or gut sterilized 2 weeks after the last CCl 4 injection until they were sacrificed (n = 8). Livers were stained for Ki-67 and cleaved-caspase 3 followed by quantification (C). Correlation between the number of cleaved-caspase 3 positive cells and tumor number, size, and liver:body weight ratio was determined (D).
(E) Nos2, Birc3, and Birc5 mRNA levels were compared between livers from Tlr4 WT (n = 12) and Tlr4 mut (n = 9) mice and between untreated wildtype mice (WT, n = 9) and antibiotics-treated wildtype mice (Abx, n = 6) Tlr4 WT mice. Data are represented as means ± SD. *p < 0.05. See also Figure S6 .
previous studies showing promotion of growth factor signaling and tumor development by ECM-rich and stiff environment (Levental et al., 2009; Samuel et al., 2011) , it is likely that growth factors and ECM produced by hepatic stellate cells synergize in tumor promotion. Our results are consistent with recent studies showing TLR4-and MyD88/Trif-dependent regulation of epiregulin and regeneration after injury in the intestine (Brandl et al., 2010; Hsu et al., 2010) . However, HCC reduction in epiregulin-deficient mice was less pronounced than in Tlr4 mut or gut-sterilized mice, suggesting that additional mechanisms contribute to TLR4-dependent HCC promotion. The most significant contribution of the intestinal microbiota in our study occurred during later stages of hepatocarcinogenesis independently of CCl 4 -induced upregulation of growth factors and regenerative responses. These results are remarkably similar to a previous study in which NF-kB inhibition at late, but not early, stages reduced inflammation-associated HCC (Pikarsky et al., 2004) . In line with this study, we detected decreased induction of NF-kB regulated genes and an increased rate of apoptosis in all groups that were protected from HCC development. Accordingly, we found that the hepatocyte compartment which had been unresponsive to LPS in healthy livers became highly sensitive to LPS in DEN plus CCl 4 -injured livers. The biological relevance of increased apoptosis for HCC development is emphasized by the strong inverse correlation of tumor number, tumor size, and liver:body weight ratio with cleavedcaspase 3-positive cells in two sets of gut-sterilized mice and in Tlr4 mut mice. In addition to its role in Abcb4 KO chronic liver
The Intestinal Microbiota, TLR4, and HCC injury model (Pikarsky et al., 2004) , hepatocellular NF-kB also acts a promoter of hepatocarcinogenesis in lymphotoxin-driven HCC (Haybaeck et al., 2009) , suggesting a requirement for hepatocellular NF-kB in HCC occurring in the setting of significant inflammation. In contrast, hepatocellular inactivation of NF-kB in genotoxic HCC models enhances hepatocarcinogenesis Maeda et al., 2005) . Finally, the complete but rather unphysiological absence of NF-kB activity by Nemo or TAK1 deletion causes chronic hepatocyte injury, liver cirrhosis, and spontaneous HCC (Bettermann et al., 2010; Inokuchi et al., 2010; Luedde et al., 2007) . Thus, the presence of inflammation and the degree of NF-kB inhibition appear to be crucial factors that determine whether NF-kB promotes or inhibits hepatocarcinogenesis. The majority of apoptosis in our study occurred in nontumor areas of the liver suggesting that prosurvival signals provided by the intestinal microbiota and TLR4 are required for the survival of tumor precursors and that apoptosis prevents the development of tumor lesions rather than leading to regression of already established tumors. Accordingly, we observed no effect of gut sterilization on already established HCCs. These results are consistent with previous findings that gene expression profiles in nontumor liver tissue, including gene sets related to NF-kB, TNFa, and interferon signaling-all downstream targets of TLR4-are crucial determinants of tumor recurrence, whereas tumor profiles have no prognostic value (Hoshida et al., 2008) .
One important difference between our findings and many previous studies is the tumor-promoting effect of inflammatory signals in resident liver cells. Bone-marrow-derived cells such as macrophages are abundant sources of inflammatory cytokines and contribute to genotoxic HCC (Maeda et al., 2005) . Our studies in chimeric mice demonstrate that bone-marrowderived cells including hepatic macrophages do not mediate the tumor-promoting effects of TLR4 in both acute and longterm HCC models. Accordingly, we found that both hepatic stellate cells and hepatocytes are targets of LPS in the liver with TLR4 on hepatic stellate cells most likely mediating regenerative response after injury and TLR4 on hepatocytes preventing apoptosis of hepatocytes and premalignant cells. Oval cells represent another potential target of LPS and LPS-induced mediators such as TNFa (Brooling et al., 2005 ), but we found only few areas with A6-and cytokeratin-positive cells typical of oval cells in our tumor model and no influence of TLR4 status and gut sterilization on the number of these cells. Further studies in mice with conditional TLR4 deletion are required to distinguish the relative contribution of TLR4 expressed in hepatocytes versus TLR4 expressed in hepatic stellate cells to hepatocarcinogenesis.
Together with results from a previous study (Pikarsky et al., 2004) , our data suggest that chronic liver injury affects the resident liver compartment and makes resident liver cells and/or tumor-forming cells more dependent on inflammatory signals for their survival. With the majority of HCCs occurring in chronically injured livers but many mouse models lacking chronic injury, it is possible that the contribution of inflammatory pathway to human HCC has been underestimated. Our results differ from a previous study in which bone-marrow-derived cell populations were suggested to promote HCC through TLR4 .
Notably, conclusions on the contribution of bone marrow were based on acute responses to DEN instead of HCC development in that study. Moreover, TLR4-and MyD88-dependent carcinogenesis in the intestine and hepatic carcinogenesis in HCV transgenic mice are also promoted by resident cells (Hsu et al., 2010; Lee et al., 2010; Machida et al., 2009; Rakoff-Nahoum and Medzhitov, 2007) . In the latter study, TLR4 promotes HCC in alcohol-treated HCV transgenic mice through the upregulation of stem cell markers. Although we observed a strong increase in the stem cell marker prominin 1/CD133 in HCCs, we observed no influence of TLR4 status on its expression in our microarray analysis, suggesting that there may be additional mechanisms by which TLR4 promotes hepatocarcinogenesis in alcoholtreated HCV transgenic mice.
To enable bone marrow transplantation studies in adult mice, our study took advantage of the high HCC susceptibility of the C3H strain and used The presented data provide conclusive evidence that the intestinal microbiota exerts a profound influence on HCC promotion in the chronically injured liver. Moreover, our study provides a strong rationale for targeting the intestinal microbiota and TLR4 for the primary or secondary prevention of HCC. The astounding reduction of HCC by gut sterilization at late stages suggests that these treatments might exert protective effects even in advanced liver disease. HCC has become the major cause of death in patients with compensated liver cirrhosis, and there is a need for more effective treatment and preventative strategies (Bruix et al., 2004) . To translate our findings into clinical medicine, clinically feasible methods of targeting the intestinal microbiota or TLR4 need to be established. The quadruple combination of antibiotics used in the present study almost completely decontaminated the intestine and prevented 80% of murine HCCs but is not suitable for long-term treatment due to known side effects in patients with advanced liver disease. Our study suggests that rifaximin, a nonabsorbable antibiotic that is widely used in patients with advanced liver disease (Bass et al., 2010) , may moderately reduce HCC development. Further studies are required to determine if longer treatment duration or combination with other well-tolerated antibiotics could improve the effects of rifaximin or if other approaches such as TLR4 antagonists would reduce HCC development.
from Jackson Laboratories. Ereg-deficient mice in a C57Bl/6 background were obtained from the Mouse Mutant Regional Resource Center at the University of North Carolina.
In C3H/HeOuJ and C3H/HeJ mice, HCC was induced by intraperitoneal (i.p.) injection of DEN (100 mg/kg) at ages 6-14 weeks followed by 6-12 biweekly injections of carbon tetrachloride (0.5 ml/kg i.p., dissolved in corn oil) unless stated otherwise. For Ereg-deficient mice and C57Bl/6 wild-type controls, HCC was induced by the combination of DEN (25 mg/kg i.p.) given at Day 15 postpartum and 22 weekly injections of CCl 4 (0.5 ml/kg i.p., dissolved in corn oil). For Tlr2 KO mice and C57Bl/6 wild-type controls, HCC was induced by the combination of DEN (100 mg/kg, i.p.) given at the age of 8 weeks, followed by 25 biweekly injections of CCl 4 (0.5 ml/kg, i.p., dissolved in corn oil). Gut sterilization was done as previously described (Rakoff-Nahoum et al., 2004; Seki et al., 2007 ) using a combination of ampicillin (1 g/l), neomycin (1 g/l), metronidazole (1 g/l), and vancomycin (500 mg/l) in drinking water. For rifaximin studies, mice received either 250 mg/l rifaximin in drinking water with rifaximin dissolved in Ora-Plus/ Ora-Sweet (Cober et al., 2010) or Ora-Plus/Ora-Sweet vehicle translating to a rifaximin dose of 50 mg/kg/day. GF mouse experiments were performed at the University of North Carolina National Gnotobiotic Rodent Resource Center, Chapel Hill, NC. All mice received DEN (25 mg/kg i.p.) in the GF status at Day 15 postpartum. One week after DEN, 50% of mice were moved to an SPF environment. Four weeks after the DEN injection, GF and SPF mice received a total of 10 CCl 4 injections (1 injection per week, at 0.5 ml/kg i.p. in corn oil). GF status was confirmed by biweekly monitoring for the presence of bacteria in the feces by aerobic and anaerobic culture as well as Gram staining of the stool. Mice were sacrificed 30 weeks after the initial DEN injection. Evaluation of tumor number and size was determined as described by counting the number of visible tumors and measuring the size of the largest tumor with a caliper (Naugler et al., 2007) . After sacrifice, livers were explanted, digitally photographed, and weighed to calculate the liver:body weight ratio. To evaluate acute effects of TLR4 and the intestinal microbiota, adult mice were treated with DEN (100 mg/kg i.p.) alone or in combination with either two or four injections of CCl 4 (0.5 ml/kg i.p.), two injections of thioacetamide (400 mg/kg i.p.) or 4 weeks of a choline-deficient L-amino-acid-defined diet. For some experiments, mice were treated with lipsomomal clodronate or liposome vehicles (200 ml i.p.). For some experiments, liver fibrosis was induced by ligating the common bile duct as previously described (Kluwe et al., 2010; Seki et al., 2007) . All animal procedures were in accordance to guidelines by the National Institutes of Health and approved by the Institutional Animal Care and Use Committee at Columbia University and the Institutional Animal Care and Use Committee at the University of North Carolina, Chapel Hill.
Human Samples and Cells
Patients with clinical, analytical, and histological features of alcoholic hepatitis were prospectively obtained in the Liver Unit of the Hospital Clínic, Barcelona, between January 2009 and December 2010 (n = 10). Liver biopsies were obtained using a transjugular approach. In all patients, liver specimens were analyzed by an expert liver pathologist. Fragments of normal livers were obtained from optimal cadaveric liver donors (n = 2) or resection of liver metastases (n = 2). All controls had normal serum aminotransferase levels and normal liver histology. Human hepatic stellate cells were isolated by density gradient-based centrifugation from normal liver as described (Kluwe et al., 2010) and used between passages 3 and 5. Procedures involving human materials were approved by the Investigational Review Board of the Hospital Clínic of Barcelona, and informed consent was obtained from all subjects.
Primary Cell Isolations
Primary hepatic stellate cells, Kupffer cells, and hepatocytes were isolated from either normal or DEN plus 23 CCl 4 -treated mice using retrograde liver perfusion and isolation techniques as previously described (Seki et al., 2007) . For some experiments, hepatic stellate cells were infected with an adenovirus expressing IkB superrepressor (AdIkBsr) or an empty control adenovirus as described elsewhere (Seki et al., 2007) .
ACCESSION NUMBERS
Microarray information was deposited at the Gene Expression Omnibus database (http://www.ncbi.nlm.nih.gov/geo/) with the accession number GSE33446.
SUPPLEMENTAL INFORMATION
Supplemental Information includes six figures and Supplemental Experimental Procedures and can be found with this article online at doi:10.1016/j.ccr.2012. 02.007.
